ResearcherStony Brook UniversityActive in the last 2 years

A.S. Pal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-7546-942X; OpenAlex author ID A5082461989. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omton.2024.200769 ↗
Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer. Co-author DOI 10.3390/ijms242417523 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jingfang Ju · 2 shared papers, 2023–2024 · strength 0.55
- Paper Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer. DOI 10.3390/ijms242417523 ↗
- Paper Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma. DOI 10.1016/j.omton.2024.200769 ↗
Andrew T. Fesler · 1 shared paper, 2024 · strength 0.24
- Paper Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma. DOI 10.1016/j.omton.2024.200769 ↗
John G. Yuen · 1 shared paper, 2024 · strength 0.24
- Paper Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma. DOI 10.1016/j.omton.2024.200769 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.